Search
Human Lactoferrin Peptide hLF1-11
go.drugbank.com/drugs/DB16245InvestigationalHuman Lactoferrin Peptide hLF1-11 is under investigation in clinical trial NCT00509834 (A Study on the Tolerability and Early Efficacy of Hlf1-11 in Patients With Proven Candidaemia).
Synonyms: N-terminal peptide of human lactoferrin 1-11Mitiperstat
go.drugbank.com/drugs/DB18963InvestigationalMitiperstat is under investigation in clinical trial NCT05492877 (An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.).
Pegmusirudin
go.drugbank.com/drugs/DB19220InvestigationalPegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).
Tirabrutinib
go.drugbank.com/drugs/DB15227InvestigationalTirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).
Salicylamide
go.drugbank.com/drugs/DB08797ApprovedSalicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies … Salicylamide is a non-prescription drug with analgesic and antipyretic properties. It has similar medicinal uses to aspirin.
Ritobegron
go.drugbank.com/drugs/DB12080InvestigationalRitobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male
Zeaxanthin
go.drugbank.com/drugs/DB11176ApprovedInvestigationalZeaxanthin is a most common carotenoid alcohols found in nature that is involved in the xanthophyll cycle. … As a coexistent isomer of lutein, zeaxanthin is synthesized in plants and some micro-organisms.
Cediranib
go.drugbank.com/drugs/DB04849InvestigationalThe novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer